Welcome to Cytochroma

Dr. Lewis is serving as President and CEO of Novocell, Inc. Prior to joining Novocell, Dr. Lewis served as CEO and Director of Signal Pharmaceuticals before its acquisition in 2000 by Celgene, a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for cancer and immunological diseases. He then served as President of the Signal Research Division at Celgene. Dr. Lewis previously held the position of Vice President of Research at Wyeth-Ayerst, where he spent 15 years leading research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. Dr. Lewis also currently serves as a Director of Sosei Group and BioMarin Pharmaceutical, Inc. Dr. Lewis received a B.Sc. in Physiology and Biochemistry from Southampton University, Southampton, Hampshire, U.K., a Ph.D. in Pharmacology from the University of Wales, Cardiff, U.K. and an Honorary Fellow and Chair of the Life Sciences Department at the University of Wales in Swansea, U.K.

Dr. Schifter joined Novo A/S in 2001. Prior to this he held a position as Chief Physician at the Department of Clinical Physiology and Nuclear Medicine, Glostrup Hospital, Copenhagen University and as Clinical Associate Professor at Copenhagen University. Dr. Schifter has an M.D. from Aarhus University, DMSc. from Copenhagen University and has specialist certification in Nuclear Medicine and Clinical Physiology. He also holds a Graduate Diploma in Business Administration from Copenhagen Business School. In Novo A/S, Dr. Schifter's responsibilities include all aspects of investment projects as well as business development of portfolio companies. He was a board member of Neurodan A/S until the company was successfully exited by acquisition in March 2005, and he is currently on the boards of Celltrix AB, Cytochroma Inc. and MediQuest Therapeutics, Inc.

Dr. Douville has served as Vice President on the team of GeneChem Management Inc., a leading North American life sciences venture capital fund manager, for 10 years. She is now a Partner of AgeChem Financial which manages their third fund dedicated to diseases related to ageing. She is an active member of the boards of directors of Cytochroma Inc., Ambit Biosciences Inc., and Chronogen Inc. and was also a board member of Idun Pharmaceuticals Inc. before its sale to Pfizer in 2005. Dr. Douville obtained her Ph.D. in biochemistry at the University of Ottawa, studying the role of protein kinases in oncogenesis. She then received postdoctoral training at the Imperial Cancer Research Fund in London (U.K.) where she studied oncogenes and their signal transduction pathways.

Dr. Marengère joined VenGrowth Capital Management Inc. in 2001, and has since led the growth and management of the VenGrowth Advanced Life Sciences Fund. He brings a comprehensive knowledge of many therapeutic areas, as well as breadth of strategic expertise in the biotechnology industry. During the last 10 years Dr. Marengère has worked with a broad range of opportunities and was involved in positioning many of those companies towards financial exits. Dr. Marengère possesses extensive sector-specific transactional experience. Dr. Marengère also conducted commercial research at Amgen in the fields of immunology and oncology. Dr. Marengère has served as a Director on Boards of the Company and Canadian-based companies and is currently a Director on the Boards of Aegera Therapeutics Inc., Z-Tech Canada Inc., Trillium Therapeutics Inc. and Cytochroma Inc. Dr. Marengère holds a Ph.D. in Medical Biophysics and Molecular Genetics from the University of Toronto.

Charles W. Bishop, PhD
CEO and President, Cytochroma Inc.

Dr. Bishop has over 21 years of management experience in the pharmaceutical industry across multiple disciplines including Research & Development, Regulatory Affairs, Operations, and Business Development. Dr. Bishop co-founded Proventiv Therapeutics in September 2005 where he served as President. Proventiv Therapeutics was acquired by Cytochroma Inc. in June 2006. During the period of September 1987 to June 2005, Dr. Bishop held various senior management positions at Bone Care International, Inc., a public specialty pharmaceutical company focused on developing and commercializing Vitamin D hormone therapies. Under Dr. Bishop's direction, Bone Care advanced a portfolio of proprietary Vitamin D hormones and analogs to varying stages of development for secondary hyperparathyroidism, metabolic bone disease, psoriasis and cancers of the prostate, breast and colon. Dr. Bishop was responsible for the successful preparation and prosecution of three New Drug Applications (NDAs) that ultimately led to FDA approval of a novel Vitamin D drug, named doxercalciferol, for secondary hyperparathyroidism in dialysis patients (Hectorol^® 2.5 mcg Capsules and Hectorol^® Injection) and pre-dialysis patients (Hectorol^® 0.5 mcg Capsules). Dr. Bishop’s positions with Bone Care included President, CEO, Director, Executive Vice President of Research and Development, and Chief Scientific Officer. Prior to joining Bone Care, Dr. Bishop held various management positions in the Health Care Division of the Procter & Gamble Company. Dr. Bishop completed a four-year National Institutes of Health Postdoctoral Fellowship in Vitamin D Biochemistry at the University of Wisconsin-Madison and received his Ph.D. degree in Nutritional Biochemistry from Virginia Polytechnic Institute and State University, after earning an undergraduate degree in Chemistry from the University of Virginia.